Coherus BioSciences Inc (CHRS):企業の財務・戦略的SWOT分析

◆英語タイトル:Coherus BioSciences Inc (CHRS) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH410367FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥78,600見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥117,900見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Coherus BioSciences Inc (Coherus) is a biosimilar platform company that develops and commercializes biosimilar drugs. The company’s pipeline product candidates include CHS-1701, an pegfilgrastim used to treat febrile neutropenia; CHS-0214, is an etanercept biosimilar candidate which is used for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriasis, psoriasis arthritis and rheumatoid arthritis; and CHS-1420, is a adalimumab biosimilar candidate, which is being developed to treat crohn’s disease, ulcerative colitis, and psoriasis arthritis, UDENYCA is a pegfilgrastim biosimilar, CHS-3351 a ranibizumab biosimilar, CHS-2020 a aflibercept biosimilar and CHS-131 a Selective PPAR-gamma modulator. Coherus capabilities includes process science, analytical characterization, protein production and clinical-regulatory development. The company develops drugs in collaboration with other organizations. Coherus is headquartered in Redwood City, California, the US.

Coherus BioSciences Inc Key Recent Developments

Feb 25,2021: Coherus Management to Present at Upcoming Investor Conferences
Feb 24,2021: Coherus BioSciences reports fourth quarter and full year 2020 financial results
Feb 18,2021: Coherus BioSciences to Report Fourth Quarter and Full Year 2020 Financial Results on February 24th
Feb 16,2021: Coherus Announces CFO Transition Plans
Feb 12,2021: Coherus BioSciences: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers

This comprehensive SWOT profile of Coherus BioSciences Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Coherus BioSciences Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Coherus BioSciences Inc – Key Information
Coherus BioSciences Inc – Overview
Coherus BioSciences Inc – Key Employees
Coherus BioSciences Inc – Key Employee Biographies
Coherus BioSciences Inc – Key Operational Heads
Coherus BioSciences Inc – Major Products and Services
Coherus BioSciences Inc – History
Coherus BioSciences Inc – Company Statement
Coherus BioSciences Inc – Locations And Subsidiaries
Coherus BioSciences Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Coherus BioSciences Inc – Business Description
Coherus BioSciences Inc – Corporate Strategy
Coherus BioSciences Inc – SWOT Analysis
SWOT Analysis – Overview
Coherus BioSciences Inc – Strengths
Coherus BioSciences Inc – Weaknesses
Coherus BioSciences Inc – Opportunities
Coherus BioSciences Inc – Threats
Coherus BioSciences Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Coherus BioSciences Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Coherus BioSciences Inc, Key Information
Coherus BioSciences Inc, Key Ratios
Coherus BioSciences Inc, Share Data
Coherus BioSciences Inc, Major Products and Services
Coherus BioSciences Inc, History
Coherus BioSciences Inc, Key Employees
Coherus BioSciences Inc, Key Employee Biographies
Coherus BioSciences Inc, Key Operational Heads
Coherus BioSciences Inc, Other Locations
Coherus BioSciences Inc, Subsidiaries
Coherus BioSciences Inc, Key Competitors
Coherus BioSciences Inc, SWOT Analysis
Coherus BioSciences Inc, Ratios based on current share price
Coherus BioSciences Inc, Annual Ratios
Coherus BioSciences Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Coherus BioSciences Inc (CHRS):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bajaj Finance Ltd (BAJFINANCE):企業の財務・戦略的SWOT分析
    Bajaj Finance Ltd (BAJFINANCE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Bridgford Foods Corporation:企業の戦略・SWOT・財務情報
    Bridgford Foods Corporation - Strategy, SWOT and Corporate Finance Report Summary Bridgford Foods Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Rockhopper Exploration Plc (RKH):石油・ガス:M&Aディール及び事業提携情報
    Summary Rockhopper Exploration Plc (Rockhopper Exploration) is an oil and gas company that acquires, explores and produces crude oil and natural gas properties in the Falkland Islands and the Greater Mediterranean region. The company’s portfolio of production licenses includes PL003a, PL003b, PL004a …
  • Pharmaxis Ltd (PXS)-製薬・医療分野:企業M&A・提携分析
    Summary Pharmaxis Ltd (Pharmaxis) is a pharmaceutical research company that develops and commercialize healthcare products. The company offers products such as aridol which identify twitchy and assist in diagnosing and managing asthma, and bronchitol which restores normal lung hydration, improves lu …
  • Cyanotech Corp:企業の戦略・SWOT・財務分析
    Cyanotech Corp - Strategy, SWOT and Corporate Finance Report Summary Cyanotech Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • AMW GmbH:医療機器:M&Aディール及び事業提携情報
    Summary AMW GmbH (AMW) is a pharmaceutical company that develops and manufactures drug delivery systems for treatment in the areas of oncology, neurology, dermatology and pain. The company designs and develops novel transdermal drug delivery systems, microchip controlled patches and biodegradable su …
  • Ceska rafinerska, a.s.-石油・ガス分野:企業M&A・提携分析
    Summary Ceska rafinerska, a.s. (Ceska rafinerska) is a crude oil refining company. It carries out the refining of crude oil, and production of petroleum based products. The company’s product portfolio includes automobile gasoline, diesel oil, aviation fuel, fuel oils, liquefied petroleum gas, heatin …
  • Halma Plc (HLMA):医療機器:M&Aディール及び事業提携情報
    Summary Halma Plc (Halma) develops, produces and sells life protection products to enhance personal and public health. The company’s product portfolio comprises fire detection and suppression systems, corrosion monitoring systems, gas detectors, elevator safety products, water treatment systems, aut …
  • Allison Transmission Holdings Inc:企業の戦略・SWOT・財務情報
    Allison Transmission Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Allison Transmission Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Sensorion SA (ALSEN):企業の財務・戦略的SWOT分析
    Summary Sensorion SA (Sensorion) is a biopharmaceutical company that develops therapies. The company provides treatments for vestibular and cochlear pathologies. It develops drug candidates through its technology platform for the treatment of various therapeutic areas including vestibular neuritis, …
  • AveXis Inc (AVXS):製薬・医療:M&Aディール及び事業提携情報
    Summary AveXis Inc (AveXis), formerly BioLife Cell Bank Inc, is a biotechnology company that develops innovative treatments for rare and potentially fatal neurological genetic diseases. The company offers AVXS-101, a proprietary gene therapy candidate in phase 1 targeted at the treatment of spinal m …
  • Eli Lilly and Co (LLY)-製薬・医療分野:企業M&A・提携分析
    Summary Eli Lilly and Company (Lilly) is a healthcare company that discovers, develops and markets human and animal healthcare products. The company offers medicines for cardiovascular conditions, diabetes, cancer, neurological problems, critical care, men's health and musculoskeletal problems. It a …
  • F5 Networks, Inc. (FFIV):企業の財務・戦略的SWOT分析
    F5 Networks, Inc. (FFIV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Respiri Ltd (RSH):医療機器:M&Aディール及び事業提携情報
    Summary Respiri Ltd (Respiri), formerly iSonea Ltd, is a medical technology company that develops non-invasive medical devices and mobile health applications to improve the management of chronic respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). The company’s prop …
  • Canada Post Corporation:企業の戦略・SWOT・財務情報
    Canada Post Corporation - Strategy, SWOT and Corporate Finance Report Summary Canada Post Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Frigo Pak Gida Maddeleri Sanayi ve Tic.:企業の戦略・SWOT・財務分析
    Frigo Pak Gida Maddeleri Sanayi ve Tic. - Strategy, SWOT and Corporate Finance Report Summary Frigo Pak Gida Maddeleri Sanayi ve Tic. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Visser & Smit Hanab BV:企業の戦略的SWOT分析
    Visser & Smit Hanab BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Acura Pharmaceuticals Inc (ACUR)-製薬・医療分野:企業M&A・提携分析
    Summary Acura Pharmaceuticals Inc (Acura) is a specialty pharmaceutical company that researches, develops, and commercializes tamper-resistant products to prevent the abuse and misuse of medication. The company’s proprietary technologies, Aversion, Limitx and Impede, are used to prevent product tamp …
  • Noble Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Noble Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Noble Energy Inc (Noble) is an independent energy company that explores for and produces crude oil, natural gas and natural gas liquids (NGLs). The company’s portfolio includes both US unconventiona …
  • Localiza Rent A Car SA:企業の戦略・SWOT・財務情報
    Localiza Rent A Car SA - Strategy, SWOT and Corporate Finance Report Summary Localiza Rent A Car SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆